Results for tu no hablas ingles casi verdad translation from French to English

no habla ingles (1)
no habla ingles (1)

sonate me veux tu? no dieu no maîre
what do you want from me

l'invention concerne également un mutant tel que défini ci-dessus, caractérisé en ce qu'il est choisi par les mutants présentant deux mutations telles qu'indiquées ci- après, chacune des mutations étant représentée par un triplet : lettre-chiffre-lettre, dont le chiffre indique la position de l'acide aminé muté, la lettre précédant le chiffre correspond à l'acide aminé sur lequel porte la mutation et la lettre suivant le chiffre correspond à l'acide aminé remplaçant l'acide aminé précédant le chiffre : k51 t-r52l (seq ed no : 2) k51t-r55l (seq id no : 3) k51 t-r57l (seq id no : 4) k51 t-g79 a (seq ld no : 5) k51t-k89l (seq id no : 6) k51t-e92q (seq id no : 7) r52l-r55l (seq id no : 8) r52l-r57l (seq tu no : 9) r52l-g79a (seq ld no : 10) r52l-k89l (seq id no : 11) r52l-e92q (seq ld no : 12) r55l-r57l (seq ld no : 13) r55l-g79a (seq ld no : 14) r55l-k89l (seq ld no : 15) r55l-e92q (seq id no 16) r57l-g79a (seq ld no 17) r57l-k89l (seq ld no 18) r57l-e92q (seq ld no 19) g79a-k89l (seq id no 20) g79a-e92q (seq id no 21) k89l-e92q (seq id no 22) un mutant avantageux selon la présente invention est un mutant tel que défini ci- dessus, caractérisé en ce qu'il est choisi parmi les mutants suivants : k51t-r55l (seq ld no : 3) r52l-r55l (seq ld no : 8) r52l-g79 a (seq ld no : 10) r55l-r57l (seq ld no : 13) g79a-k89l (seq tû no : 20) l'invention concerne également un mutant tel que défini ci-dessus, caractérisé en ce qu'il est choisi par les mutants présentant trois mutations telles qu'indiquées ci-après, chacune des mutations étant représentée par un triplet : lettre-chiffre-lettre, dont le chiffre indique la position de l'acide aminé muté, la lettre précédant le chiffre correspond à l'acide aminé sur lequel porte la mutation et la lettre suivant le chiffre correspond à l'acide aminé remplaçant l'acide aminé précédant le chiffre : c27s-k51t-r52l (seq id no : 23) c27s-k51t-r55l (seq id no : 24) c27s-k51t-r57l (seq id no : 25) c27s-k51t-g79a (seq tû no : 26) c27s-k51t-k89l (seq tû no : 27) c27s-k51t-e92q (seq id no : 28) c27s-r52l-r55l (seq id no : 29) c27s-r52l-r57l (seq ld no : 30) c27s-r52l-g79a (seq id no : 3.1) c27s-r52l-k89l (seq id no : 32) c27s-r52l-e92q (seq ld no : 33) c27s-r55l-r57l (seq id no : 34) c27s-r55l-g79a (seq id no : 35) c27s-r55l-k89l (seq id no : 36) c27s-r55l-e92q (seq id no : 37) c27s-r57l-g79a (seq id no : 38) c27s-r57l-k89l (seq id no : 39) c27s-r57l-e92q (seq ld no : 40) c27s-g79a-k89l (seq ld no : 41) c27s-g79a-e92q (seq id no : 42) c27s-k89l-e92q (seq id no : 43) la présente invention concerne également un mutant tel que défini ci-dessus, caractérisé en ce qu'il est choisi parmi les mutants suivants : c27s-k51t-r55l (seq id no : 24) c27s-r52l-r55l (seq ld no : 29) c27s-r52l-g79a (seq ld no : 31) la présente invention concerne un mutant tel que défini ci-dessus, caractérisé en ce qu'il est choisi par les mutants présentant quatre mutations telles qu'indiquées ci- après, chacune des mutations étant représentée par-un triplet : lettre-chiffre-lettre, dont le chiffre indique la position de l'acide aminé muté, la lettre précédant le chiffre correspond à l'acide aminé sur lequel porte la mutation et la lettre suivant le chiffre correspond à l'acide aminé remplaçant l'acide aminé précédant le chiffre : c27s-k51t-r52l-g79a (seq id no : 44) c27s-k51t-r52l-k89l (seq id no : 45) c27s-k51t-r52l-e92q (seq ld no ! 46) c27s-k51t-r55l-g79a (seq id no : 47) c27s-k51t-r55l-k89l (seq tû no : 48) c27s-k51t-r55l-e92q (seq id no : 49) c27s-k51t-r57l-g79a (seq id no : 50) c27s-k51t-r57l-k89l (seq ld no : 51) c27s-k51t-r57l-e92q (seq ld no : 52) c27s-k51t-g79a-k89l (seq tû no : 53) c27s-k51t-g79a-e92q (seq td no : 54) c27s-k51t-k89l-e92q (seq id no : 55) c27s-r52l-g79a- 89l (seq id no 56) c27s-r52l-g79a-e92q (seq id no 57) c27s-r52l-k89l-e92q (seq id no 58) c27s-r52l-r55l-g79a (seq ro no 59) c27s-r52l-r55l-k89l (seq id no 60) c27s-r52l-r55l-e92q (seq ld no 61) c27s-r52l-r57l-g79a (seq ld no 62) c27s-r52l-r57l-k89l (seq ld no 63) c27s-r52l-r57l-e92q (seq ld no 64) c27s-r55l-g79a-k89l (seq ld no 65) c27s-r55l-g79a-e92q (seq id no 66) c27s-r55l-k89l-e92q (seq ld no 67) c27s-r55l-r57l-g79a (seq ld no 68) c27s-r55l-r57l-k89l (seq ld no 69) c27s-r55l-r57l-e92q (seq id no 70) c27s-r57l-g79a-k89l (seq id no 71) c27s-r57l-g79a-e92q (seq id no 72) c27s-r57l-k89l-e92q (seq id no 73) c27s-g79a-k89l-e92q (seq id no 74) un mutant avantageux selon la présente invention est caractérisé en ce qu'il est choisi parmi les mutants suivants : c27s-k51t-r55l-g79a (seq ld no : 47) c27s-k51t-r55l-k89l (seq id no :' 48) c27s-k51t-r55l-e92q (seq id no : 49) c27s-r52l-r55l-g79a (seq id no : 59) la présente invention concerne un mutant tel que défini ci-dessus, caractérisé en ce qu'il est choisi par les mutants présentant cinq mutations telles qu'indiquées ci-après, chacune des mutations étant représentée par un triplet : lettre-chiffre-lettre, dont le chiffre indique la position de l'acide aminé muté, la lettre précédant le chiffre correspond à l'acide aminé sur lequel porte la mutation et la lettre suivant le chiffre correspond à l'acide aminé remplaçant l'acide aminé précédant le chiffre : c27s-k51t-g79a-k89l-e92q (seq id no : 75) c27s-k51t-r52l-r55l-g79a (seq id no : 76 c27s-k51t-r52l-r55l-k89l (seq ld no : 77 c27s-k51t-r52l-r55l-e92q (seq id no : 78 c27s-k51t-r52l-r57l-g79a (seq id no : 79 c27s-k51t-r52l-r57l-k89l (seq id no : 80 c27s-k51t-r52l-r57l-e92q (seqldno: 81 c27s-k51t-r52l-g79a-k89l (seq id no : 82 c27s-k51t-r52l-g79a-e92q (seq id no : 83 c27s-k51 t-r52l-k89l-e92q (seq id no : 84 c27s-k51t-r55l-r57l-g79a (seq id no : 85 c27s-k51t-r55l-r57l-k89l (seq id no : 86 c27s-k51t-r55l-r57l-e92q (seq ed no : 87 c27s-k51t-r55l-g79a-k89l (seqldno: 88 c27s-k51t-r55l-g79a-e92q (seq id no : 89 c27s-k51t-r55l-k89l-e92q (seq id no : 90 c27s-k51t-r57l-g79a-k89l (seq d o: 91 c27s-k51t-r57l-g79a-e92q (seqid o: 92 c27s-k51 t-r57l-k89l-e92q (seq id no : 93 c27s-r52l-r55l-r57l-g79a (seq id no : 94 c27s-r52l-r55l-r57l-k89l (seq id no : 95 c27s-r52l-r55l-r57l-e92q (seq ld no : 96 c27s-r52l-r55l-g79a-k89l (seq id no : 97; c27s-r52l-r55l-g79a-e92q (seq 10^0:98 c27s-r52l-r55l-k89l-e92q (seq id no : 99 c27s-r52l-r57l-g79a-k89l (seq dno: 100) c27s-r52l-r57l-g79a-e92q (seqidno: 101) c27s-r52l-r57l-k89l-e92q (seqidno: 102) c27s-r52l-g79a-k89l-e92q (seqidno: 103) c27s-r55l-r57l-g79a-k89l (seqidno: 104) c27s-r55l-r57l-g79a-e92q (seqidno: 105) c27s-r55l-r57l-k89l-e92q (seqidno: 106) c27s-r55l-g79a-k89l-e92q (seqidno: 107) c27s-r57l-g79a-k89l-e92q (seq id no : 108) un mutant avantageux selon l'invention est un mutant tel que défini ci-dessus, caractérisé en ce qu'il est choisi parmi les mutants suivants : c27s-k51t-r55l-g79a- 89l (seq id no : 88) c27s-k51t-r55l-g79a- e92q (seq ld no : 89) la présente invention concerne également des séquences nucléotidiques codant pour l'un des mutants tels que définis ci-dessus.
the invention also relates to a mutant as defined above, characterized in that it is chosen from the mutants having two mutations as indicated hereafter, each of the mutations being represented by a triplet: letter-figure-letter, the figure of which indicates the position of the mutated amino acid, the letter preceding the figure corresponds to the amino acid to which the mutation relates and the letter following the figure corresponds to the amino acid replacing the amino acid preceding the figure: k51t-r52l (seq id no: 2) k51t-r55l (seq id no: 3) k51t-r57l (seq id no: 4) k51t-g79a (seq id no: 5) k51t-k89l (seq id no: 6) k51t-e92q (seq id no: 7) r52l-r55l (seq id no: 8) r52l-r57l (seq id no: 9) r52l-g79a (seq id no: 10) r52l-k89l (seq id no: 11) r52l-e92q (seq id no: 12) r55l-r57l (seq id no: 13) r55l-g79a (seq id no: 14) r55l-k89l (seq id no: 15) r55l-e92q (seq id no: 16) r57l-g79a (seq id no: 17) r57l-k89l (seq id no: 18) r57l-e92q (seq id no: 19) g79a-k89l (seq id no: 20) g79a-e92q (seq id no: 21) k89l-e92q (seq id no: 22) an advantageous mutant according to the present invention is a mutant as defined above, characterized in that it is chosen from the following mutants: k51t-r55l (seq id no: 3) r52l-r55l (seq id no: 8) r52l-g79a (seq id no: 10) r55l-r57l (seq id no: 13) g79a-k89l (seq id no: 20) the invention also relates to a mutant as defined above, characterized in that it is chosen from the mutants having three mutations as indicated hereafter, each of the mutations being represented by a triplet: letter-figure-letter, the figure of which indicates the position of the mutated amino acid, the letter preceding the figure corresponds to the amino acid to which the mutation relates and the letter following the figure corresponds to the amino acid replacing the amino acid preceding the figure: c27s-k51t-r52l (seq id no: 23) c27s-k51t-r55l (seq id no: 24) c27s-k51t-r57l (seq id no: 25) c27s-k51t-g79a (seq id no: 26) c27s-k51t-k89l (seq id no: 27) c27s-k51t-e92q (seq id no: 28) c27s-r52l-r55l (seq id no: 29) c27s-r52l-r57l (seq id no: 30) c27s-r52l-g79a (seq id no: 31) c27s-r52l-k89l (seq id no: 32) c27s-r52l-e92q (seq id no: 33) c27s-r55l-r57l (seq id no: 34) c27s-r55l-g79a (seq id no: 35) c27s-r55l-k89l (seq id no: 36) c27s-r55l-e92q (seq id no: 37) c27s-r57l-g79a (seq id no: 38) c27s-r57l-k89l (seq id no: 39) c27s-r57l-e92q (seq id no: 40) c27s-g79a-k89l (seq id no: 41) c27s-g79a-e92q (seq id no: 42) c27s-k89l-e92q (seq id no: 43) the present invention also relates to a mutant as defined above, characterized in that it is chosen from the following mutants: c27s-k51t-r55l (seq id no: 24) c27s-r52l-r55l (seq id no: 29) c27s-r52l-g79a (seq id no: 31) the present invention relates to a mutant as defined above, characterized in that it is chosen from the mutants having four mutations as indicated hereafter, each of the mutations being represented by a triplet: letter-figure-letter, the figure of which indicates the position of the mutated amino acid, the letter preceding the figure corresponds to the amino acid to which the mutation relates and the letter following the figure corresponds to the amino acid replacing the amino acid preceding the figure: c27s-k51t-r52l-g79a (seq id no: 44) c27s-k51t-r52l-k89l (seq id no: 45) c27s-k51t-r52l-e92q (seq id no: 46) c27s-k51t-r55l-g79a (seq id no: 47) c27s-k51t-r55l-k89l (seq id no: 48) c27s-k51t-r55l-e92q (seq id no: 49) c27s-k51t-r57l-g79a (seq id no: 50) c27s-k51t-r57l-k89l (seq id no: 51) c27s-k51t-r57l-e92q (seq id no: 52) c27s-k51t-g79a-k89l (seq id no: 53) c27s-k51t-g79a-e92q (seq id no: 54) c27s-k51t-k89l-e92q (seq id no: 55) c27s-r52l-g79a-k89l (seq id no: 56) c27s-r52l-g79a-e92q (seq id no: 57) c27s-r52l-k89l-e92q (seq id no: 58) c27s-r52l-r55l-g79a (seq id no: 59) c27s-r52l-r55l-k89l (seq id no: 60) c27s-r52l-r55l-e92q (seq id no: 61) c27s-r52l-r57l-g79a (seq id no: 62) c27s-r52l-r57l-k89l (seq id no: 63) c27s-r52l-r57l-e92q (seq id no: 64) c27s-r55l-g79a-k89l (seq id no: 65) c27s-r55l-g79a-e92q (seq id no: 66) c27s-r55l-k89l-e92q (seq id no: 67) c27s-r55l-r57l-g79a (seq id no: 68) c27s-r55l-r57l-k89l (seq id no: 69) c27s-r55l-r57l-e92q (seq id no: 70) c27s-r57l-g79a-k89l (seq id no: 71) c27s-r57l-g79a-e92q (seq id no: 72) c27s-r57l-k89l-e92q (seq id no: 73) c27s-g79a-k89l-e92q (seq id no: 74) an advantageous mutant according to the present invention is characterized in that it is chosen from the following mutants: c27s-k51t-r55l-g79a (seq id no: 47) c27s-k51t-r55l-k89l (seq id no: 48) c27s-k51t-r55l-e92q (seq id no: 49) c27s-r52l-r55l-g79a (seq id no: 59) the present invention relates to a mutant as defined above, characterized in that it is chosen from the mutants having five mutations as indicated hereafter, each of the mutations being represented by a triplet: letter-figure-letter, the figure of which indicates the position of the mutated amino acid, the letter preceding the figure corresponds to the amino acid to which the mutation relates and the letter following the figure corresponds to the amino acid replacing the amino acid preceding the figure: c27s-k51t-g79a-k89l-e92q (seq id no: 75) c27s-k51t-r52l-r55l-g79a (seq id no: 76) c27s-k51t-r52l-r55l-k89l (seq id no: 77) c27s-k51t-r52l-r55l-e92q (seq id no: 78) c27s-k51t-r52l-r57l-g79a (seq id no: 79) c27s-k51t-r52l-r57l-k89l (seq id no: 80) c27s-k51t-r52l-r57l-e92q (seq id no: 81) c27s-k51t-r52l-g79a-k89l (seq id no: 82) c27s-k51t-r52l-g79a-e92q (seq id no: 83) c27s-k51t-r52l-k89l-e92q (seq id no: 84) c27s-k51t-r55l-r57l-g79a (seq id no: 85) c27s-k51t-r55l-r57l-k89l (seq id no: 86) c27s-k51t-r55l-r57l-e92q (seq id no: 87) c27s-k51t-r55l-g79a-k89l (seq id no: 88) c27s-k51t-r55l-g79a-e92q (seq id no: 89) c27s-k51t-r55l-k89l-e92q (seq id no: 90) c27s-k51t-r57l-g79a-k89l (seq id no: 91) c27s-k51t-r57l-g79a-e92q (seq id no: 92) c27s-k51t-r57l-k89l-e92q (seq id no: 93) c27s-r52l-r55l-r57l-g79a (seq id no: 94) c27s-r52l-r55l-r57l-k89l (seq id no: 95) c27s-r52l-r55l-r57l-e92q (seq id no: 96) c27s-r52l-r55l-g79a-k89l (seq id no: 97) c27s-r52l-r55l-g79a-e92q (seq id no: 98) c27s-r52l-r55l-k89l-e92q (seq id no: 99) c27s-r52l-r57l-g79a-k89l (seq id no: 100) c27s-r52l-r57l-g79a-e92q (seq id no: 101) c27s-r52l-r57l-k89l-e92q (seq id no: 102) c27s-r52l-g79a-k89l-e92q (seq id no: 103) c27s-r55l-r57l-g79a-k89l (seq id no: 104) c27s-r55l-r57l-g79a-e92q (seq id no: 105) c27s-r55l-r57l-k89l-e92q (seq id no: 106) c27s-r55l-g79a-k89l-e92q (seq id no: 107) c27s-r57l-g79a-k89l-e92q (seq id no: 108) an advantageous mutant according to the invention is a mutant as defined above, characterized in that it is chosen from the following mutants: c27s-k51t-r55l-g79a-k89l (seq id no: 88) c27s-k51t-r55l-g79a-e92q (seq id no: 89) the present invention also relates to nucleotide sequences coding for one of the mutants as defined above.